Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention

• Published in: Cancer Medicine
• Main Authors: Dovey de la Cour, Cecilie, Guleria, Sonia, Nygård, Mari, Trygvadóttir, Laufey, Sigurdsson, Kristjan, Liaw, Kai‐Li, Hortlund, Maria, Lagheden, Camilla, Hansen, Bo T., Munk, Christian, Dillner, Joakim, Kjaer, Susanne K.
• Other Authors: Merck
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2019
• Subjects: Norway; Iceland
• Online Access: http://dx.doi.org/10.1002/cam4.1961; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.1961; https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1961

Abstract It is valuable to establish a population‐based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high‐grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer ( P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and representative baselines for assessing and evaluating the population‐based preventive impact of HPV vaccination.